shares of Eton Pharmaceuticals Inc (ETON) on
Eton Pharmaceuticals, Inc. engages in the development and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 11 full-time employees. The company products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The firm focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.